According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. “
Several other analysts have also recently commented on NTLA. BidaskClub upgraded shares of Intellia Therapeutics from a sell rating to a hold rating in a research report on Thursday, February 6th. Raymond James upgraded shares of Intellia Therapeutics from a market perform rating to an outperform rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital restated a buy rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research report on Monday, February 10th. Finally, ValuEngine cut shares of Intellia Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $25.25.
Shares of Intellia Therapeutics stock opened at $13.86 on Tuesday. The firm has a fifty day moving average of $14.27 and a two-hundred day moving average of $14.54. The stock has a market capitalization of $677.51 million, a price-to-earnings ratio of -7.04 and a beta of 2.82. Intellia Therapeutics has a 52 week low of $10.26 and a 52 week high of $19.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.89 and a current ratio of 7.89.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $35,000. Wealthcare Advisory Partners LLC acquired a new position in Intellia Therapeutics in the 4th quarter worth $37,000. Exchange Traded Concepts LLC acquired a new position in Intellia Therapeutics in the 4th quarter worth $56,000. Bank of Montreal Can boosted its stake in Intellia Therapeutics by 32.8% in the 4th quarter. Bank of Montreal Can now owns 5,258 shares of the company’s stock worth $77,000 after purchasing an additional 1,300 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Intellia Therapeutics by 69.6% in the 4th quarter. Victory Capital Management Inc. now owns 8,514 shares of the company’s stock worth $125,000 after purchasing an additional 3,493 shares during the period. Institutional investors and hedge funds own 90.10% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Recommended Story: What member countries make up the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.